Kyowa Hakko Kirin hit with a new PhIII setback on an old Parkinson’s drug
Eight years after Japan’s Kyowa Hakko Kirin was handed an FDA rejection for its Parkinson’s drug istradefylline (KW-6002), researchers say they recorded a Phase III flop for the drug.
The drug, approved in Japan, is designed to reduce the amount of daily off-time patients experience with levodopa. But while Kyowa Hakko’s team tracked a trend in favor of the 20 mg and 40 mg doses, they did not hit statistical significance.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.